Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database

J Psychopharmacol. 2013 Apr;27(4):358-65. doi: 10.1177/0269881112473789. Epub 2013 Jan 23.

Abstract

The aim was to explore weight and body mass index (BMI) changes by baseline BMI in patients completing three years of monotherapy with various first- and second-generation antipsychotics in a large cohort in a post hoc analysis of three-year observational data. Data were analyzed by antipsychotic and three baseline BMI bands: underweight/normal weight (BMI <25 kg/m²), overweight (25-30 kg/m²) and obese (>30 kg/m²). Baseline BMI was associated with subsequent weight change irrespective of the antipsychotic given. Specifically, a smaller proportion of patients gained ≥7% baseline bodyweight, and a greater proportion of patients lost ≥7% baseline bodyweight with increasing baseline BMI. For olanzapine (the antipsychotic associated with highest mean weight gain in the total drug cohort), the percentage of patients gaining ≥7% baseline weight was 45% (95% CI: 43-48) in the underweight/normal weight BMI cohort and 20% (95% CI: 15-27) in the obese BMI cohort; 7% (95% CI: 6-8) of the underweight/normal cohort and 19% (95% CI: 13-27) of the obese cohort lost ≥7% baseline weight. BMI has an association with the likelihood of weight gain or loss and should be considered in analyses of antipsychotic weight change.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Benzodiazepines / adverse effects
  • Benzodiazepines / therapeutic use
  • Body Mass Index
  • Cohort Studies
  • Databases, Factual
  • Female
  • Global Health
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Obesity / chemically induced
  • Obesity / complications*
  • Obesity / prevention & control
  • Olanzapine
  • Overweight / chemically induced
  • Overweight / complications*
  • Overweight / prevention & control
  • Prospective Studies
  • Schizophrenia / complications
  • Schizophrenia / drug therapy*
  • Serotonin Uptake Inhibitors / adverse effects
  • Serotonin Uptake Inhibitors / therapeutic use
  • Thinness / chemically induced
  • Thinness / complications*
  • Thinness / prevention & control
  • Weight Gain / drug effects
  • Weight Loss / drug effects

Substances

  • Antipsychotic Agents
  • Serotonin Uptake Inhibitors
  • Benzodiazepines
  • Olanzapine